AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04634968 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General health communication
Description: Telephone peer counselling+ General health communication, and telephone-based interview, and telephone-based interview after receiving all information.
Study NCT04295304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retinal surgery with implantation of epi-retinal device
Description: Retinal surgery and implantation of epi-retinal prosthesis
Study NCT02392546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elobixibat
Study NCT02392546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01898546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary angioplasty
Description: Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
Study NCT01898546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Description: Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
Study NCT01898546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Description: 1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
Study NCT00087204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Description: Given IV
Study NCT00087204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01852344 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: 20 mgs of methylphenidate or placebo to be administered one hour before task performance
Study NCT01852344 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 20 mgs of methylphenidate or a placebo to be administered one hour before task performance
Study NCT01852344 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Easy Behavioral Task
Description: Subjects do an easy version of the Letter E Task.
Study NCT01852344 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hard Behavioral Task
Description: Subjects do a hard version of the Letter E Task.
Study NCT00410280 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IMA-638 is a biologic
Study NCT03482310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system
Description: Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
Study NCT00790296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone (TRH)
Description: 0.5mg and 1.5mg
Study NCT00790296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02183298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - intravenous
Study NCT02183298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - Tablet
Study NCT02183298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02225067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium (13C)Carbonate
Description: Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
Study NCT02014532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
Study NCT02014532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
Study NCT04561817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipatasertib
Description: 400mg PO daily: day 1-21 of 28 day cycle
Study NCT04561817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
Study NCT03550716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mTESE
Description: mTESE is performed according to the initial description by Schlegel (4). General anesthesia is used. Midline incision of the scrotum is made and carried down to the level of the tunica vaginalis, which is opened to deliver the testis. Equatorial incision is made and the testis bivalved. The operating microscope is used to identify plump-appearing seminiferous tubules, and biopsies are taken from these areas. These samples are examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24G angiocatheter. The procedure is stopped if spermatozoa are found. If no plump tubules are found, random biopsies targeting every area of the testis are taken. If necessary the procedure is carried out on the contralateral testis. Hemostasis is obtained with careful bipolar cautery, and the tunica albuginea and the tunica vaginalis are closed with a running 4-0 Vicryl. Standard scrotal closure is performed and gentle pressure dressing is applied.
Study NCT03550716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TESA
Description: In general anesthesia an 18 gauge needle is introduced into each testis, and negative pressure applied with a 10 ml syringe. Multiple passes throughout the entire testis, numbering 50-100 passes, are made through a single percutaneous/tunical entry and continued until tissue is visible in the hub of the needle. This is removed by brisk extraction of the needle and pressure held to tamponade bleeding. The aspirated tissue is examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24 gauge angiocatheter.
Study NCT01214616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib 20mg
Description: patient to receive afatinib low dose po daily in combination with vinorelbine iv
Study NCT01214616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib 40mg
Description: patient to receive afatinib high dose po daily in combination with vinorelbine iv
Study NCT01214616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine IV 25 or 20mg/m2
Description: patient to receive standard dose vinorelbine once a week for four times per cycle
Study NCT01116245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADXS11-001 (Lm-LLO-E7)
Description: ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
Study NCT01116245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: 3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
Study NCT02596347 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
Study NCT02596347 — intervention group
Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
Study NCT04533763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based Mindful Living program
Description: The program is delivered using web-based group conferencing. During each session, participants are taught new stress management and coping techniques. Each week there is opportunity to apply techniques to real world situations for practice. Participants have a group orientation session, and then meet for 10 weeks. Group sessions last 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post- randomization. Program includes training in mindfulness, cognitive behavioral stress management, relaxation, imagery, prioritizing meaningful activities, communication, and coping strategies. Content is geared toward concerns of cancer survivors.
Study NCT04533763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology-based Healthy Lifestyles program
Description: The program is delivered using web-based group conferencing. Sessions include content from the National Cancer Institute, American Cancer Society, and health care providers with expertise in oncology. All content is geared to promoting healthy living among ovarian cancer survivors. Participants have a group orientation session, and then meet for 10 weeks, with group sessions lasting 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post-randomization. Healthy Lifestyle sessions include topics such as nutrition, exercise, sleep, quality of life, survivorship, and cognitive function with content geared toward concerns of cancer survivors.
Study NCT03984448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT03984448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT03984448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT03984448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT03984448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03984448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT03984448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03984448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03984448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03984448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02844465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visualase MRI-Guided Laser Ablation
Description: All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
Study NCT01919554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 500 IR house dust mites allergen extract tablet
Description: One sublingual tablet daily during 10 days
Study NCT01919554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1000 IR house dust mites allergen extract tablet
Description: Two sublingual tablets daily during 10 days
Study NCT01919554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1500 IR house dust mites allergen extract tablet
Description: Three sublingual tablets daily during 10 days
Study NCT01919554 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: One, two or three sublingual placebo tablets daily during 10 days matching with the sublingual immunotherapy tablets
Study NCT01087554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase.
Study NCT01087554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.
Study NCT01087554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase.
Study NCT01087554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase.
Study NCT03487822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Path Pain
Description: The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
Study NCT03279250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03279250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT03581630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion
Description: Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
Study NCT03581630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone/bupropion
Description: Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
Study NCT03581630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
Study NCT03581630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
Study NCT02864836 — intervention group
Intervention type: PROCEDURE
Intervention: Samples collection
Description: 5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
Study NCT03792269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intraperitoneal
Study NCT03792269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: intravenous
Study NCT03792269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study NCT01359826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
Study NCT01359826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran
Description: After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
Study NCT03162783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Solution (0.5%)
Description: ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
Study NCT03968445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714-PET/MRI
Description: \[18F\]DPA-714-PET/MRI
Study NCT03718104 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetic analysis
Description: Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
Study NCT03162783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Solution (0.1%)
Description: ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
Study NCT04634903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy SSI
Description: Online, 30-minute self-administered program for youth
Study NCT04634903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation SSI
Description: Online, 30-minute self-administered program for youth
Study NCT03162783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Lipid Solution (0.5%)
Description: ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
Study NCT03718104 — intervention group
Intervention type: OTHER
Intervention: Safety and Efficacy
Description: Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).
Study NCT03718104 — intervention group
Intervention type: GENETIC
Intervention: Genetic and epigenetic analysis
Description: Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.
Study NCT03718104 — intervention group
Intervention type: OTHER
Intervention: Breast milk analysis
Description: Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
Study NCT04634903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset SSI
Description: Online, 30-minute self-administered program for youth
Study NCT03438422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pollen extract
Description: 1 tablet a day
Study NCT00664053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHEA
Description: 50mg daily for 6 months
Study NCT00664053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: 50mg daily for 6 months
Study NCT00664053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 2 sessions per week for 6 months
Study NCT00664053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: 2 sessions per week for 6 months
Study NCT00664053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo supplement every day for 6 months
Study NCT02916914 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Q2 feeding
Description: Infants are going to be fed every 2 hours
Study NCT03438422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pollen extract
Description: 1 tablet a day
Study NCT00664053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement every day for 6 months
Study NCT00664053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobics
Description: Walking/chair aerobics program 2 sessions per week for 6 months
Study NCT00664053 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobics
Description: Walking/chair aerobics program 2 sessions per week for 6 months
Study NCT01139216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
Study NCT01139216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
Study NCT01139216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.